Trial record 1 of 1 for:    C27002
Previous Study | Return to List | Next Study

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02083185
Recruitment Status : Completed
First Posted : March 11, 2014
Last Update Posted : November 22, 2017
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )

Brief Summary:
This is a 3-arm, randomized, open-label, parallel group study of TAK-385, together with a leuprorelin observational cohort, in patients with prostate cancer who require first-line androgen deprivation therapy (ADT).

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: TAK-385, 80 mg Drug: TAK-385, 120 mg Drug: Leuprorelin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 133 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer
Study Start Date : April 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Leuprorelin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: TAK-385, 80 mg
80 mg orally daily
Drug: TAK-385, 80 mg
Experimental: TAK-385, 120 mg
120 mg orally daily
Drug: TAK-385, 120 mg
Active Comparator: Leuprorelin
22.5 mg
Drug: Leuprorelin

Primary Outcome Measures :
  1. Rate of effective castration defined as the estimated proportion of patients who have testosterone concentrations < 50 ng/dL at all scheduled visits [ Time Frame: Between Day 1 of Week 5 and Day 1 of Week 25 ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: From screening to 30 days after last dose of study drug up to 53 weeks ]
    Including vital signs, Physical examination findings, Clinical laboratory test results, and adverse events (AEs) and serious adverse events.

  2. Prostate-specific antigen (PSA) response at 4 weeks [ Time Frame: Week 5, Day 1 ]
  3. PSA nadir [ Time Frame: During weeks 1-24 ]
  4. Serum PSA concentration [ Time Frame: At the end of Week 12 and Week 24 ]
  5. TAK-385 plasma concentrations for population PK/PD analysis [ Time Frame: Various timepoints in weeks 1-49 ]
  6. Quality-of-life using 25-item Prostate Cancer Module [P25] of the EORTC, Aging Male Survery (AMS), and EORTC QLQ-C30 [ Time Frame: At regular intervals during treatment, during 3 month after the end of dosing follow-up, when applicable, and/or at the end-of-study (EOS) visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  1. Male patients 18 years or older
  2. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  3. Candidate for androgen deprivation therapy (ADT) for the management of hormone-sensitive prostate cancer with 1 of the following clinical disease states: 1) advanced localized disease not suitable for primary therapy, 2) evidence of prostate-specific antigen (PSA) biochemical or clinical relapse following primary surgery or radiation therapy of curative intent, or 3) newly diagnosed metastatic disease that is asymptomatic or not threatening to vital organs
  4. Appropriate serum testosterone and serum PSA concentration at screening as specified in the protocol
  5. A body mass index (BMI) ≥ 18.0 at screening and/or baseline
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening and/or baseline.
  7. Male patients, even if surgically sterilized, who agree to practice effective barrier contraception or agree to practice true abstinence.
  8. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
  9. Suitable venous access for the study-required blood sampling, including PK and PD Sampling

Exclusion Criteria

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  1. In patients with advanced, localized M0N1 or M1 disease, the presence of clinically significant symptoms or threat to vital organs requiring immediate GnRH/CAB therapy, chemotherapy, or radiotherapy
  2. Previously received ADT for more than 8 months total duration (if ADT was received for 8 months or less, then that ADT must have been completed at least 2 years prior to screening)
  3. Visceral metastases (liver or lung)
  4. Features of the patient's medical condition that may make ADT unnecessary or not indicated.
  5. Scheduled for additional surgical or (salvage) radiation therapy within 6 months after baseline evaluations
  6. History of surgical castration
  7. Diagnosis of or treatment for another malignancy within the 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
  8. Abnormal screening and/or baseline laboratory values as specified in the protocol
  9. History of any significant cardiac condition within 6 months before receiving the first dose of study drug
  10. ECG abnormalities as specified in the protocol
  11. Congenital long QT syndrome
  12. Current use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications
  13. Uncontrolled hypertension despite appropriate medical therapy. Patients may be re-screened after referral and further management of hypertension
  14. Known, previously diagnosed human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to prostate cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study. Specific screening for chronic viral illness is at the discretion of the site and/or local institutional review board (IRB)
  15. Treatment with any investigational products within 3 months before the first dose of study drug
  16. A primary family member (spouse, parent, child, or sibling of the patient) is involved in the conduct of the study or is a study site employee
  17. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-385, including difficulty swallowing tablets
  18. Use of any medication, or food products listed in the excluded medications and dietary products table within 2 weeks before the first dose of study drug. Patient must have no history of amiodarone use in the 6 months before the first dose of TAK-385
  19. Admission or evidence of alcohol or drug abuse or use of illicit drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02083185

  Show 23 Study Locations
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.

Responsible Party: Millennium Pharmaceuticals, Inc. Identifier: NCT02083185     History of Changes
Other Study ID Numbers: C27002
U1111-1162-5028 ( Registry Identifier: WHO )
172837 ( Registry Identifier: HC-CTD )
First Posted: March 11, 2014    Key Record Dates
Last Update Posted: November 22, 2017
Last Verified: November 2016

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases